MacDonald Marnie L, Lamerdin Jane, Owens Stephen, Keon Brigitte H, Bilter Graham K, Shang Zhidi, Huang Zhengping, Yu Helen, Dias Jennifer, Minami Tomoe, Michnick Stephen W, Westwick John K
Odyssey Thera, Inc. 4550 Norris Canyon Rd. Suite 140, San Ramon, California 94583, USA.
Nat Chem Biol. 2006 Jun;2(6):329-37. doi: 10.1038/nchembio790. Epub 2006 May 7.
We present a strategy for identifying off-target effects and hidden phenotypes of drugs by directly probing biochemical pathways that underlie therapeutic or toxic mechanisms in intact, living cells. High-content protein-fragment complementation assays (PCAs) were constructed with synthetic fragments of a mutant fluorescent protein ('Venus', EYFP or both), allowing us to measure spatial and temporal changes in protein complexes in response to drugs that activate or inhibit particular pathways. One hundred and seven different drugs from six therapeutic areas were screened against 49 different PCA reporters for ten cellular processes. This strategy reproduced known structure-function relationships and also predicted 'hidden,' potent antiproliferative activities for four drugs with novel mechanisms of action, including disruption of mitochondrial membrane potential. A simple algorithm identified a 25-assay panel that was highly predictive of antiproliferative activity, and the predictive power of this approach was confirmed with cross-validation tests. This study suggests a strategy for therapeutic discovery that identifies novel, unpredicted mechanisms of drug action and thereby enhances the productivity of drug-discovery research.
我们提出了一种策略,通过直接探测完整活细胞中构成治疗或毒性机制基础的生化途径,来识别药物的脱靶效应和隐藏表型。利用突变荧光蛋白(“金星”、增强型黄色荧光蛋白或两者)的合成片段构建了高内涵蛋白质片段互补分析(PCA),使我们能够测量蛋白质复合物在响应激活或抑制特定途径的药物时的时空变化。针对六个治疗领域的107种不同药物,针对49种不同的PCA报告基因进行了十种细胞过程的筛选。该策略重现了已知的结构-功能关系,还预测了四种具有新作用机制(包括破坏线粒体膜电位)的药物的“隐藏”、强效抗增殖活性。一种简单的算法确定了一个25项分析的面板,该面板对抗增殖活性具有高度预测性,并且这种方法的预测能力通过交叉验证测试得到了证实。这项研究提出了一种治疗发现策略,该策略可识别新的、未预测到的药物作用机制,从而提高药物发现研究的效率。